See the latest news and media coverage for Ultragenyx. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing treatments for rare diseases
ultragenyx.comLast updated
In short: Ultragenyx secured FDA approval for its first gene therapy but saw shares plunge after a Phase 3 trial for a bone disease drug failed.
The investigational antisense oligonucleotide missed cognitive and responder endpoints while maintaining its established safety profile. The company will reassess the program and implement cost reductions to support commercial operations.
The company examined LC-FAOD and GSDIa management strategies through clinical case studies while pledging continued support for patients with inherited disorders.
This first-in-class treatment targets glycogen storage disease type Ia by enabling normal glucose metabolism and significantly reducing patient reliance on burdensome cornstarch regimens.
Investors and stakeholders receive comprehensive earnings data alongside strategic progress details in the official corporate announcement.
Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the publication of 96-week data from its Phase 3 study of GENGLYCOS™ AAV gene therapy (pariglasgene brecaparvovec-opnr), also...
Regeneron wins ultra-rare disease drug approval, a validating win for mRNA research, and more biotech news from The Readout...
Ultragenyx (RARE) Q2 2026 earnings call: record revenue, reaffirmed guidance, key PDUFA dates for DTX401/UX111 and GTX-102 data—read now.
Track Ultragenyx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Ultragenyx and other trending companies.